ImmuneOnco Advances Timdarpacept to Phase III After Strong Leukemia Trial Data

The latest update is out from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ).

ImmuneOnco Biopharmaceuticals reported audited annual results for 2025, highlighting significant clinical progress in its oncology pipeline, particularly its core asset timdarpacept. The company positions itself as a specialized cancer drug developer with a focus on blood malignancies and combination regimens that may improve outcomes over existing standards of care.

During the year, Phase II trials of IMM01 with azacitidine for first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia met their primary endpoints, showing high overall response rates and favorable tolerability. Building on these data, the company secured regulatory approval in China to launch a Phase III trial for IMM01 in CMML, began dosing in late 2024, and had enrolled more than 100 patients by the end of 2025, underscoring its transition toward late-stage development and potential future commercialization.

The most recent analyst rating on (HK:1541) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.

More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a China-based biopharmaceutical company focused on oncology, developing innovative immunotherapies targeting blood cancers. Its core product candidate, timdarpacept (IMM01), is a SIRPα-Fc fusion protein being advanced primarily in combination with azacitidine for higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Average Trading Volume: 1,718,570

Technical Sentiment Signal: Sell

Current Market Cap: HK$3.81B

For an in-depth examination of 1541 stock, go to TipRanks’ Overview page.